Peter N. Helvey

Array ( [id] => 20638761 [patent_doc_number] => 20260097110 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-04-09 [patent_title] => BETACORONAVIRUS mRNA VACCINES [patent_app_type] => utility [patent_app_number] => 19/410927 [patent_app_country] => US [patent_app_date] => 2025-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 81726 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19410927 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20040932 [patent_doc_number] => 20250179154 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-06-05 [patent_title] => NEUTRALIZING ANTIBODIES TO GP120 AND THEIR USE [patent_app_type] => utility [patent_app_number] => 19/035336 [patent_app_country] => US [patent_app_date] => 2025-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42806 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19035336 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20343138 [patent_doc_number] => 12466860 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-11 [patent_title] => Methods for using dual glycan binding AAV vectors [patent_app_type] => utility [patent_app_number] => 19/006818 [patent_app_country] => US [patent_app_date] => 2024-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 15680 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 133 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19006818 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19982998 [patent_doc_number] => 20250121220 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-17 [patent_title] => BETACORONAVIRUS mRNA VACCINES [patent_app_type] => utility [patent_app_number] => 19/000377 [patent_app_country] => US [patent_app_date] => 2024-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 82048 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19000377 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19982999 [patent_doc_number] => 20250121221 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-17 [patent_title] => BETACORONA VIRUS mRNA VACCINES [patent_app_type] => utility [patent_app_number] => 19/000472 [patent_app_country] => US [patent_app_date] => 2024-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 79484 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19000472 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19961833 [patent_doc_number] => 12331321 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2025-06-17 [patent_title] => Alpha-herpesvirus insensitive monoclonal cell strain, and preparation method therefor and use thereof [patent_app_type] => utility [patent_app_number] => 18/964018 [patent_app_country] => US [patent_app_date] => 2024-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 19 [patent_no_of_words] => 0 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18964018 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19554957 [patent_doc_number] => 20240366749 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => COMBINATION HMPV/RSV RNA VACCINES [patent_app_type] => utility [patent_app_number] => 18/762384 [patent_app_country] => US [patent_app_date] => 2024-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 85448 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18762384 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19730301 [patent_doc_number] => 12208288 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-28 [patent_title] => Betacoronavirus RNA vaccines [patent_app_type] => utility [patent_app_number] => 18/762372 [patent_app_country] => US [patent_app_date] => 2024-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 41 [patent_no_of_words] => 85519 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18762372 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20212712 [patent_doc_number] => 12409347 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-09 [patent_title] => Betacoronavirus mRNA vaccines [patent_app_type] => utility [patent_app_number] => 18/762296 [patent_app_country] => US [patent_app_date] => 2024-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 41 [patent_no_of_words] => 81605 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18762296 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19624112 [patent_doc_number] => 12162916 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-10 [patent_title] => Compositions targeting apoptosis-associated speck-like protein with caspase activation and recruitment domain (ASC) and methods of use [patent_app_type] => utility [patent_app_number] => 18/637070 [patent_app_country] => US [patent_app_date] => 2024-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 12892 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18637070 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19447398 [patent_doc_number] => 20240307528 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => METHODS OF BOOSTING AN IMMUNE RESPONSE AGAINST HIV USING COMMENSAL MICROBE ANTIGENS [patent_app_type] => utility [patent_app_number] => 18/606343 [patent_app_country] => US [patent_app_date] => 2024-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14627 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18606343 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19755721 [patent_doc_number] => 20250044286 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-06 [patent_title] => SOLUTION-BASED PLASMONIC SPECIFIC-BINDING PARTNER ASSAYS USING METALLIC NANOSTRUCTURES [patent_app_type] => utility [patent_app_number] => 18/605728 [patent_app_country] => US [patent_app_date] => 2024-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16054 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18605728 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19265627 [patent_doc_number] => 20240209326 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-27 [patent_title] => BACTERIAL DELIVERY VEHICLE, PROCESS OF PRODUCTION AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/598495 [patent_app_country] => US [patent_app_date] => 2024-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29346 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18598495 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19418487 [patent_doc_number] => 20240294610 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-05 [patent_title] => PEPTIDE FOR TREATING AGE-RELATED MACULAR DEGENERATION [patent_app_type] => utility [patent_app_number] => 18/597675 [patent_app_country] => US [patent_app_date] => 2024-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29912 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18597675 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20206333 [patent_doc_number] => 20250276053 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-09-04 [patent_title] => ROTAVIRUS VACCINES [patent_app_type] => utility [patent_app_number] => 18/593328 [patent_app_country] => US [patent_app_date] => 2024-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18680 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18593328 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19232228 [patent_doc_number] => 20240189419 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-13 [patent_title] => METHOD FOR THE PROPHYLAXIS OR TREATMENT OF CORONAVIRUS INFECTION USING AN IMMUNOMODULATOR AND VACCINE COMPOSITIONS COMPRISING THE SAME [patent_app_type] => utility [patent_app_number] => 18/583389 [patent_app_country] => US [patent_app_date] => 2024-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4633 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18583389 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19404033 [patent_doc_number] => 20240287544 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => MODIFIED PIV5 VACCINE VECTORS: METHODS OF MAKING AND USES [patent_app_type] => utility [patent_app_number] => 18/433149 [patent_app_country] => US [patent_app_date] => 2024-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27672 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18433149 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19170983 [patent_doc_number] => 20240156957 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => MODULATORS OF MYC, METHODS OF USING THE SAME, AND METHODS OF IDENIFYING AGENTS THAT MODULATE MYC [patent_app_type] => utility [patent_app_number] => 18/423395 [patent_app_country] => US [patent_app_date] => 2024-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26962 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18423395 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19479822 [patent_doc_number] => 20240327864 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-03 [patent_title] => DIAPHRAGM-SPECIFIC NUCLEIC ACID REGULATORY ELEMENTS AND METHODS AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/417465 [patent_app_country] => US [patent_app_date] => 2024-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25576 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18417465 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19722793 [patent_doc_number] => 20250025544 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-23 [patent_title] => IMMUNE CHECKPOINT INHIBITOR CO-EXPRESSION VECTORS [patent_app_type] => utility [patent_app_number] => 18/404681 [patent_app_country] => US [patent_app_date] => 2024-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64318 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 255 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18404681 [rel_patent_id] =>[rel_patent_doc_number] =>)